genedrive
plc
("genedrive" or the
"Company")
NICE Early Value Assessment
update
genedrive plc (AIM: GDR),
the point of care Pharmacogenetic testing company, notes the
opening of the NICE Early Value Assessment ("EVA") evidence
generation funding call, supported by the National Institute for
Health and Care Research (NIHR). The programme works in
collaboration with the Office for Life Sciences (OLS) and the
National Institute for Health and Care Excellence (NICE).
The Real World Evidence Programme is backed by £10
million of government funding, as part of the UK Government's Life
Sciences Vision.
The programme is aimed at addressing
real world evidence gaps to accelerate widespread adoption of
technologies, that have been recommended for use in the NHS through
the NICE EVA framework.
Genedrive confirms that it is in the
process of submitting an application for funding to address the
NICE EVA evidence generation recommendations of the Genedrive® MT-RNR1 ID Kit, which
are required for progressing the NICE conditional recommendation
into a full recommendation.
Further details of the programme,
which is due to start in October 2024 can be found here:
https://www.nihr.ac.uk/funding/nihr-i4i-and-ols-real-world-evidence-programme/34713
James Cheek, Chief Executive Officer of genedrive plc,
said: "We are delighted that
funding is to be made available for the real world evidence
generation for the NICE EVA technologies to achieve full NICE
guidance. This gives the potential for our Genedrive® MT-RNR1 ID
Kit to move from a conditional recommendation to a full
recommendation with NICE, and accelerate adoption of the kit in the
NHS."
For further details, please
contact:
genedrive plc
|
+44 (0)161
989 0245
|
James Cheek: CEO / Russ Shaw:
CFO
|
|
|
|
Peel
Hunt LLP (Nominated Adviser and Broker)
|
+44 (0)20
7418 8900
|
James Steel / Patrick
Birkholm
|
|
|
|
Walbrook PR Ltd (Media & Investor
Relations)
|
+44 (0)20
7933 8780 or genedrive@walbrookpr.com
|
Anna Dunphy
|
+44
(0)7876 741 001
|
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a pharmacogenetic
testing company developing and commercialising a low cost, rapid,
versatile, simple to use and robust point of need pharmacogenetic
platform for the diagnosis of genetic variations. This
helps clinicians to quickly access key genetic
information that will help them make the right choices over the
right medicine or dosage to use for an effective treatment.
Based in the UK, the Company is at the forefront
of work on Point of Care pharmacogenetics. Pharmacogenetics looks
at how your genetics impacts a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicines can be made safer
and more effective. The Company has
launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a single-use disposable cartridge that circumvents the
requirement for cold chain logistics by providing temperature
stable reagent test kits for use on their proprietary test
platform. This test allows clinicians to make a decision on
antibiotic use within 26 minutes; ensuring vital care is delivered
with no negative impact on the patient pathway.
The Company has a clear commercial
strategy focused on accelerating growth through maximising
in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in
Manchester.